Download PDF
Thromb Haemost 1990; 63(02): 187-192
DOI: 10.1055/s-0038-1645193
Original Article
Schattauer GmbH Stuttgart

Inhibition by Recombinant Hirudins of Experimental Venous Thrombosis and Disseminated Intravascular Coagulation Induced by Tissue Factor in Rats

Monique Freund
1   INSERM U.311, Biologie et Pharmacologie des Interactions du Sang avec les Vaisseaux et les Biomatériaux, Centre Régional de Transfusion Sanguine, Strasbourg, France
,
Jean-Pierre Cazenave
1   INSERM U.311, Biologie et Pharmacologie des Interactions du Sang avec les Vaisseaux et les Biomatériaux, Centre Régional de Transfusion Sanguine, Strasbourg, France
,
Michael Courtney
2   INSERM U.311, Transgéne SA, Strasbourg, France,
,
Eric Degryse
2   INSERM U.311, Transgéne SA, Strasbourg, France,
,
Carolyn Roitsch
2   INSERM U.311, Transgéne SA, Strasbourg, France,
,
André Bernat
3   INSERM U.311, Sanofi Recherche, Ligne Hémobiologie, Toulouse, France
,
Denis Delebassée
3   INSERM U.311, Sanofi Recherche, Ligne Hémobiologie, Toulouse, France
,
Guy Defreyn
3   INSERM U.311, Sanofi Recherche, Ligne Hémobiologie, Toulouse, France
,
Jean-Pierre Maffrand
3   INSERM U.311, Sanofi Recherche, Ligne Hémobiologie, Toulouse, France
› Author Affiliations
Further Information

Publication History

Received 15 November 1988

Accepted after revision 20 November 1989

Publication Date:
02 July 2018 (online)

  PDF Download  Permissions and Reprints

Summary

Antithrombotic potency of recombinant hirudins rHV2, rHV2–Lys47 and rHV2–Arg47 was studied in a model of experimental thrombosis induced by tissue factor in the rat. Venous thrombosis was induced by i.v. injection of 25 mg/kg tissue factor followed by stasis of the inferior vena cava. In this model natural recombinant hirudins, rHV2 and rHV2–Lys47 injected 5 min before thromboplastin totally inhibited thrombosis in the same μg range as heparin or natural hirudin extracted from leeches. However, the mutant variant rHV2–Arg47 gave a maximal 60% inhibition of thrombosis. Variants rHV2–Lys47 (30 μg/kg) and rHV2–Arg47 (157 μg/kg) injected 5 min before thromboplastin prevented by 90 to 100% the drop in platelet count observed during the disseminated intravascular coagulation induced by thromboplastin injection. Recombinant hirudins were less anticoagulant than heparin as measured by an APTT on rat plasma. After rat tail transection, rHV2–Lys47 caused a 2–fold smaller prolongation of the bleeding time than an equivalent antithrombotic dose of heparin. Plasmatic elimination of rHV2–Lys47 from rat plasma after i.v. injection had a fast distribution phase with a half-life of 3 min during which 90% of injected rHV2–Lys47 was lost and was followed by a slower elimination phase. Thus recombinant hirudin rHV2–Lys47 appears as a promising potent antithrombotic agent for the prevention of thrombin-dependent venous thrombosis and disseminated intravascular coagulation

 

  • References

  • 1 Markwardt F. The comeback of hirudin, an old-established anticoagulant agent. Folia Haematol Leipzig 1988; 115: 10-23
    PubMedGoogle Scholar
  • 2 Markwardt F. Hirudin as an inhibitor of thrombin. In: Methods in Enzymology, Vol. 29 Academic Press; New York: 1970. pp 924-932
  • 3 Stone SR, Hofsteenge J. Kinetics of the inhibition of thrombin by hirudin. Biochemistry 1986; 25: 4622-4628
    CrossrefPubMedGoogle Scholar
  • 4 Markwardt F, Hauptmann J, Nowak G, Kleßen C, Walsmann P. Pharmacological studies on the antithrombotic action of hirudin in experimental animals. Thromb Haemostas 1982; 47: 226-229
    PubMedGoogle Scholar
  • 5 Markwardt F, Nowak G, StÜrzebecher J, Grießbaeh U, Walsmann P, Vogel G. Pharmacokinetics and anticoagulant effect of hirudin in man. Thromb Haemostas 1984; 52: 160-163
    PubMedGoogle Scholar
  • 6 Harvey RP, Degryse E, Stefani L, Schamber F, Cazenave J-P, Courtney M, Tolstoshev P, Lecocq J-P. Cloning and expression of a cDNA coding for the anticoagulant hirudin from the bloodsucking leech, Hirudo medicinalis. Proc Natl Acad Sci USA 1986; 83: 1084-1088
    CrossrefPubMedGoogle Scholar
  • 7 Loison G, Findeli A, Bernard S, Nguyen-Juilleret M, Marquet M, Riehl-Bellon N, Carvallo D, Guerra-Santos L, Brown SW, Courtney M, Roitsch C, Lemoine Y. Expression and secretion in S. cerevisiae of biologically active leech hirudin. Biotechnology 1988; 6: 72-7
    CrossrefPubMedGoogle Scholar
  • 8 Dodt J, Schmitz T, Schafer T, Bergmann C. Expression, secretion and processing of hirudin in E. coli using the alkaline phosphatase signal sequence. FEBS Lett 1986; 202: 373-377
    CrossrefPubMedGoogle Scholar
  • 9 Bergmann C, Dodt J, Köhler S, Fink E, Gassen HG. Chemical synthesis and expression of a gene coding for hirudin, the thrombin-specific inhibitor from the leech Hirudo medicinalis . Biol Chem Hoppe-Seyler 1986; 367: 731-740
    PubMedGoogle Scholar
  • 10 Fortkamp E, Rieger M, Heistberg-Moutses G, Schweitzer S, Sommer R. Cloning and expression in Escherichia coli of a synthetic DNA for hirudin, the blood coagulation inhibitor in the leech. DNA 1986; 5: 511-517
    CrossrefPubMedGoogle Scholar
  • 11 Meyhack B, Heim J, Rink H, Zimmermann W, Maerki W. Desulfatohirudin, a specific thrombin inhibitor: expression and secretion in yeast. Thromb Res 1987; Suppl VII 33
    PubMedGoogle Scholar
  • 12 Krstenansky J, Mao SJ T. Antithrombin properties of C-terminus of hirudin using synthetic unsulfated Nα-acetyl-hirudin45–65 . FEBS Lett 1987; 211: 10-16
    CrossrefPubMedGoogle Scholar
  • 13 Konno S, Fenton JW II, Villanueva GB. Analysis of the secondary structure of hirudin and the mechanism of its interaction with thrombin. Arch Biochem Biophys 1988; 267: 158-166
    CrossrefPubMedGoogle Scholar
  • 14 Braun PJ, Dennis S, Hofsteenge J, Stone SR. Use of site-directed mutagenesis to investigate the basis for the specificity of hirudin. Biochemistry 1988; 27: 6517-6522
    CrossrefPubMedGoogle Scholar
  • 15 Chang J-Y. The structures and proteolytic specificities of autolysed human thrombin. Biochem J 1986; 240: 797-802
    CrossrefPubMedGoogle Scholar
  • 16 Chang J-Y. The hirudin binding site of human α-thrombin. Identification of lysyl residues which participate in the combining site of hirudin-thrombin complex. J Biol Chem 1989 264. 7141-7146
    PubMedGoogle Scholar
  • 17 Chang J-Y. The functional domain of hirudin, a thrombin specific inhibitor. FEBS Lett 1983; 164: 307-313
    CrossrefPubMedGoogle Scholar
  • 18 Dodt J, Köhler S, Baici A. Interaction of site specific hirudin variants with α-thrombin. FEBS Lett 1988; 229: 87-90
    CrossrefPubMedGoogle Scholar
  • 19 Dejana E, Villa S, de Gaetano G. Bleeding time in rats: a comparison of different experimental conditions. Thromb Haemostas 1982; 48: 108-111
    PubMedGoogle Scholar
  • 20 Riehl-Bellon N, Carvallo D, Acker M, Van Dorsselaer A, Marquet M, Loison G, Lemoine Y, Brown SW, Courtney M, Roitsch C. Purification and biochemical characterization of recombinant hirudin produced by Saccharomyces cerevisiae . Biochemistry 1989; 28: 2941-2949
    CrossrefPubMedGoogle Scholar
  • 21 Van Dorsselaer A, Lepage P, Bitsch F, Whitechurch O, Riehl-Bellon N, Fraisse D, Green B, Roitsch C. Mass spectrometry analyses of recombinant hirudins (7 kDa). Biochemistry 1989; 28: 2949-2956
    CrossrefPubMedGoogle Scholar
  • 22 Degryse E, Acker M, Defreyn G, Bernat A, Maffrand J-P, Roitsch C, Courtney M. Point mutations modifying the thrombin inhibition kinetics and antithrombotic activity in vivo of recombinant hirudin. Prolein Eng 1989; 2: 459-465
    PubMedGoogle Scholar
  • 23 Freyssinet J-M, Gauchy J, Cazenave J-P. The effect of phospholipids on the activation of protein C by the human thrombin-thrombomodulin complex. Biochem J 1986; 238: 151-157
    CrossrefPubMedGoogle Scholar
  • 24 Regoeczi E. Iodine-labeled Plasma Proteins. CRC Press; Boca Raton, FL: 1984. pp 49-56
  • 25 Singlas E, Tabaret A-M. In:. Abrégé de pharmacocinétique; Hoechst Biologie: 1987. pp 47-50
  • 26 Ringler DH, Dabich L. Hematology and clinical biochemistry. In: The Laboratory Rat, Biology and Diseases Vol. 1 Baker HJ, Lindsey JR, Weisbroth SH. eds. Academic Press; New York: 1979. p 108
  • 27 Griessbach U, StÜrzebecher J, Markwardt F. Assay of hirudin in plasma using a chromogenic thrombin substrate. Thromb Res 1985; 37: 347-350
    CrossrefPubMedGoogle Scholar
  • 28 Wessler S, Reimer SM, Sheps MC. Biologic assay of a thrombosis-inducing activity in human serum. J Appl Physiol 1959; 14: 943-946
    CrossrefPubMedGoogle Scholar
  • 29 Reyers I, Mussoni L, Donati MB, de Gaetano G. Failure of aspirin at different doses to modify experimental thrombosis in rats. Thromb Res 1980; 18: 669-674
    CrossrefPubMedGoogle Scholar
  • 30 Fareed J, Wallenga JM, Kumar A, Rock A. A modified stasis model to study the antithrombotic actions of heparin and its fractions. Semin Thromb Haemostas 1985; 11: 155-175
    Article in Thieme ConnectPubMedGoogle Scholar
  • 31 Markwardt F, Fink G, Kaiser B, Klöcking HP, Nowak G, Richter M, StÜrzebecher T. Pharmalogical survey of recombinant hirudin. Pharmazie 1988; 43: 202-207
    PubMedGoogle Scholar
  • 32 Talbot MD, Ambler J, Butler KD, Findlay VS, Mitchell KA, Peters RF, Tweed MF, Wallis RB. Recombinant desulphatohirudin (CGP 39393) anticoagulant and antithrombotic properties in vivo. Thromb Haemostas 1989; 61: 77-80
    PubMedGoogle Scholar
  • 33 Markwardt F, Kaiser B, Nowak G. Studies of antithrombotic effects of recombinant hirudin. Thromb Res 1989; 54: 377-388
    CrossrefPubMedGoogle Scholar
  • 34 Doutremepuich C, Deharo E, Guyot M, Lalanne MC, Walenga J, Fareed J. Antithrombotic activity of recombinant hirudin in the rat: a comparative study with heparin. Thromb Res 1989; 54: 435-445
    CrossrefPubMedGoogle Scholar
  • 35 Kaiser B, Markwardt F. Antithrombotic and haemorrhagic effects of synthetic and naturally occurring thrombin inhibitors. Thromb Res 1986; 43: 613-620
    CrossrefPubMedGoogle Scholar
  • 36 Markwardt F, Nowak G, StÜrzebecher J, Vogel G. Clinico-pharmalogical studies with recombinant hirudin. Thromb Res 1988; 52: 393-400
    CrossrefPubMedGoogle Scholar